Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin B6 deficiency as a cause of erythropoietin-stimulating agent-resistant anemia in hemodialysis patients: A report of two cases.

Internal medicine (Tokyo, Japan)·2026
Same author

Primary diffuse leptomeningeal glioblastoma: Report of two cases.

Surgical neurology international·2026
Same author

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026
Same author

Histological Features of Lung Squamous Cell Carcinoma According to Radiological Early-Phase Progression Patterns.

Pathology international·2026
Same author

Reversible transdiaphragmatic downward herniation: A unique manifestation of immunoglobulin G4-related disease.

Clinical neurology and neurosurgery·2026
Same author

Azathioprine withdrawal leading to spontaneous remission of Iatrogenic Epstein-Barr virus-negative diffuse large B-cell lymphoma: A case report and literature review.

Internal medicine (Tokyo, Japan)·2026

Related Experiment Video

Updated: Jul 13, 2025

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

19.8K

Possible New Histological Prognostic Index for Large B-Cell Lymphoma.

Hideaki Nitta1, Haruko Takizawa1, Toru Mitsumori1

  • 1Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan.

Journal of Clinical Medicine
|October 14, 2023
PubMed
Summary

A new Histological Prognostic Index (HPI) identifies large B-cell lymphoma (LBCL) treatment resistance. Negative GRP94/CYP3A4 indicates good prognosis, while positive GRP94/CYP3A4 suggests poor outcomes.

Keywords:
CYP3A4P53aldo-keto reductase family 1 member C3 (AKR1C3)glucose-regulated protein 94 (GRP94)immunohistochemical (IHC) staininglarge B-cell lymphoma (LBCL)multidrug resistance protein 1 (MDR1)multidrug resistance-associated protein 1 (MRP1)

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples
09:58

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples

Published on: January 7, 2019

8.8K

Related Experiment Videos

Last Updated: Jul 13, 2025

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

19.8K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples
09:58

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples

Published on: January 7, 2019

8.8K

Area of Science:

  • Oncology
  • Biochemistry
  • Immunohistochemistry

Background:

  • Large B-cell lymphoma (LBCL) treatment resistance remains a clinical challenge.
  • Understanding the molecular mechanisms of drug metabolism and resistance is crucial for improving patient outcomes.
  • The CHOP regimen is a standard treatment, but individual responses vary significantly.

Observation:

  • Retrospective analysis of 42 LBCL patients utilizing immunohistochemical (IHC) staining for 17 factors.
  • Key factors analyzed included ER stress protein GRP94, p53, and CHOP regimen metabolism factors (AKR1C3, CYP3A4, MDR1, MRP1).
  • Logistic regression identified MDR1, MRP1, and AKR1C3 as significant predictors of complete remission (CR) versus non-CR/relapse.

Findings:

  • A novel Histological Prognostic Index (HPI) was developed, categorizing patients into four groups: Very Good, Good, Poor, and Very Poor.
  • Very Good prognosis (5-year OS 100%) associated with negative GRP94 and CYP3A4 staining.
  • Very Poor prognosis (1-year OS 0%) associated with positive GRP94 and CYP3A4 staining.
  • Good prognosis (5-year OS 60-80%) linked to negative MDR1 and AKR1C3 staining.
  • Poor prognosis (5-year OS 10-20%) linked to positive MDR1, AKR1C3, MRP1, or p53 staining.

Implications:

  • The HPI offers a breakthrough method for stratifying LBCL patients based on predicted treatment resistance.
  • This index can guide personalized treatment strategies and clinical trial design.
  • Further validation of the HPI in larger cohorts is warranted to confirm its clinical utility.